Cargando…

Structural variants shape the genomic landscape and clinical outcome of multiple myeloma

Deciphering genomic architecture is key to identifying novel disease drivers and understanding the mechanisms underlying myeloma initiation and progression. In this work, using the CoMMpass dataset, we show that structural variants (SV) occur in a nonrandom fashion throughout the genome with an incr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashby, Cody, Boyle, Eileen M., Bauer, Michael A., Mikulasova, Aneta, Wardell, Christopher P., Williams, Louis, Siegel, Ariel, Blaney, Patrick, Braunstein, Marc, Kaminetsky, David, Keats, Jonathan, Maura, Francesco, Landgren, Ola, Walker, Brian A., Davies, Faith E., Morgan, Gareth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151656/ https://www.ncbi.nlm.nih.gov/pubmed/35637217 http://dx.doi.org/10.1038/s41408-022-00673-x

Ejemplares similares

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2017)

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
por: Bauer, Michael A., et al.
Publicado: (2020)

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2020)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer
por: Ghamlouch, Hussein, et al.
Publicado: (2021)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
por: Maclachlan, Kylee H., et al.
Publicado: (2021)

The evolving role and utility of off-label drug use in multiple myeloma
por: Stoeckle, James H, et al.
Publicado: (2021)

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
por: Caro, Jessica, et al.
Publicado: (2022)

3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns
por: Schinke, Carolina, et al.
Publicado: (2019)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
por: Oben, Bénedith, et al.
Publicado: (2021)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2020)

TarPan: an easily adaptable targeted sequencing panel viewer for research and clinical use
por: Ashby, Cody, et al.
Publicado: (2020)

FiNGS: high quality somatic mutations using filters for next generation sequencing
por: Wardell, Christopher Paul, et al.
Publicado: (2021)

Author Correction: Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2021)

Management of multiple myeloma during COVID-19 pandemic
por: Jethava, YS, et al.
Publicado: (2020)

Biological determinants of health disparities in multiple myeloma
por: Smith, Cheryl Jacobs, et al.
Publicado: (2018)

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
por: Landgren, Ola, et al.
Publicado: (2023)

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
por: Walker, Brian A., et al.
Publicado: (2018)

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
por: Boyle, Eileen M, et al.
Publicado: (2015)

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
por: Schinke, Carolina, et al.
Publicado: (2020)

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
por: Stein, Caleb K., et al.
Publicado: (2017)

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Search for rare protein altering variants influencing susceptibility to multiple myeloma
por: Scales, Matthew, et al.
Publicado: (2017)

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
por: Jones, John R., et al.
Publicado: (2019)

Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway
por: Liu, Enze, et al.
Publicado: (2023)

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
por: Biran, Noa, et al.
Publicado: (2019)

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
por: Sudha, Parvathi, et al.
Publicado: (2022)

Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress
por: Bright, Michael D., et al.
Publicado: (2015)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tn71mbh6krr34uu757ifhl0ikj